Back to search

Belgium· BE-AMP-SAM535057-00

Kymriah 1,2 x 10*6 – 6 x 10*8 cells

A tisagenlecleucel product containing tisagenlecleucel, registered in Belgium by Novartis Europharm. The same ATC class is registered in 11 of our 19 countries.

ATC L01XL04

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedKymriah 1,2 x 10*6 – 6 x 10*8 cellsATCL01XL04REGISTER NO.BE-AMP-SAM535057-00PACKS LISTED11CHECKEDSeptember 26, 2026

Where it is registered

Tisagenlecleucel is registered in 11 of 19 countries.

Countries holding a registration under ATC L01XL04 (tisagenlecleucel), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 7 of them publish a price we can compare per daily dose

Tisagenlecleucel · ATC L01XL04

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Tisagenlecleucel
Manufacturer
Novartis Europharm
Country
Belgium (BE)
ATC code
L01XL04
ATC class
Tisagenlecleucel
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 11

  • be_apb
    7725104
  • be_apb
    7740566
  • be_apb
    7725070
  • be_apb
    7725088
  • be_apb
    7725096
  • be_apb
    3953502
  • be_apb
    7725047
  • be_apb
    7725054
  • be_apb
    7725062
  • be_apb
    7725112
  • be_apb
    7725120

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

60 interactions on record for tisagenlecleucel.

Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Tisagenlecleucel · interactions on record

60 records

  • 28 severe
  • 32 moderate

Most severe, free to view

  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Tisagenlecleucel in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tisagenlecleucel products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Kymriah
  • Liechtenstein · Kymriah
  • Norway · Kymriah

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/75207b5f-3e17-4ab1-b56a-d1ee011ba025
GET /v1/drugs/75207b5f-3e17-4ab1-b56a-d1ee011ba025?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Dispersion for infusion",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Kymriah 1,2 x 10*6 – 6 x 10*8 cells",
  "name_fr": "Kymriah 1,2 x 10*6 – 6 x 10*8 cells",
  "name_nl": "Kymriah 1,2 x 10*6 – 6 x 10*8 cells",
  "amp_code": "SAM535057-00",
  "strengths": [
    "2.4300"
  ],
  "pack_count": 1,
  "substances": [
    "Tisagenlecleucel",
    "Dimethyl Sulfoxide",
    "Glucose",
    "Potassium Chloride",
    "Sodium"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Tisagenlecleucel",
  "authorisation_numbers": [
    "EU/1/18/1297/001"
  ]
}

See everything about tisagenlecleucel.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.